254
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Validation of an Algorithm to Identify Venous Thromboembolism in Health Insurance Claims Data Among Patients with Rheumatoid Arthritis

, , , , ORCID Icon, & show all
Pages 671-682 | Received 22 Dec 2022, Accepted 16 May 2023, Published online: 01 Jun 2023

References

  • Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012;64(1):53–61. doi:10.1002/art.33322
  • Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308(13):1350–1356. doi:10.1001/2012.jama.11741
  • Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res. 2013;65(10):1600–1607.
  • Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73(10):1774–1780. doi:10.1136/annrheumdis-2013-203380
  • Cushman M, Barnes GD, Creager MA, et al. Venous thromboembolism research priorities: a scientific statement from the American Heart Association and the International Society on Thrombosis and Haemostasis. Circulation. 2020;142(6):e85–e94. doi:10.1161/CIR.0000000000000818
  • Bell EJ, Lutsey PL, Basu S, et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129(3):339.e19–e26. doi:10.1016/j.amjmed.2015.10.014
  • Liang H, Danwada R, Guo D, et al. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open. 2019;5(2):e001013. doi:10.1136/rmdopen-2019-001013
  • Molander V, Bower H, Frisell T, Askling J. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169–175. doi:10.1136/annrheumdis-2020-218419
  • Gavrielov-Yusim N, Friger M. Use of administrative medical databases in population-based research. J Epidemiol Commun Health. 2014;68(3):283–287. doi:10.1136/jech-2013-202744
  • Wang SV, Schneeweiss S, Berger ML, et al. Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf. 2017;26(9):1018–1032. doi:10.1002/pds.4295
  • Beyrer J, Abedtash H, Hornbuckle K, Murray JF. A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms. J Comp Eff Res. 2022;11(7):499–511. doi:10.2217/cer-2022-0006
  • Weinstein EJ, Ritchey ME, Lo Re V. Core concepts in pharmacoepidemiology: validation of health outcomes of interest within real-world healthcare databases. Pharmacoepidemiol Drug Saf. 2023;32(1):1–8. doi:10.1002/pds.5537
  • Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):154–162. doi:10.1002/pds.2341
  • Baumgartner C, Go AS, Fan D, et al. Administrative codes inaccurately identify recurrent venous thromboembolism: the CVRN VTE study. Thromb Res. 2020;189:112–118. doi:10.1016/j.thromres.2020.02.023
  • Fang MC, Fan D, Sung SH, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care. 2017;55(12):e137–e143. doi:10.1097/MLR.0000000000000524
  • Molander V, Bower H, Askling J. Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis. Scand J Rheumatol. 2022;1:1–7.
  • Verma AA, Masoom H, Pou-Prom C, et al. Developing and validating natural language processing algorithms for radiology reports compared to ICD-10 codes for identifying venous thromboembolism in hospitalized medical patients. Thromb Res. 2022;209:51–58. doi:10.1016/j.thromres.2021.11.020
  • Salinas CA, Louder A, Polinski J, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2022;13:1–23. doi:10.1007/s40744-022-00505-1
  • Schumock GT, Lee TA, Pickard AS, et al. Alternative methods for health outcomes of interest validation. Mini-Sentinel Methods; 2013. Available from: https://www.sentinelinitiative.org/sites/default/files/surveillance-tools/validations-literature/Mini-Sentinel-Alternative-Methods-for-Health-Outcomes-of-Interest-Validation_0.pdf. Accessed September 26, 2022.
  • Tenny S, Hoffman MR. Prevalence. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.